[Editor's Note: Attend the MassChallenge Awards Ceremony to celebrate startups on October 23rd, 2012. The event is part of Innovation Week in Massachusetts during which time 8 conferences are happening simultaneously. Join the conversation on Twitter #InnoWeekMA]
When did you start Cellanyx and what got you all together to work on this?
Cellanyx Diagnostics is a development stage company innovating in-vitro tissue and cell culturing techniques for use in research and in-vitro diagnostics. Leveraging a novel suite of biomarkers, microfluidic technology and computational techniques, Cellanyx Diagnostics will offer a quantitative and objective diagnostic for prostate cancer.
Cellanyx's technology has been under development since 2009. After placing first-runner up at the 2011 MIT 100K in the life science's category, Cellanyx's team has been steadily growing and now consists of 5 full-time and 7 part-time employees. Cellanyx's team is passionate about the solution and technology it is applying to the growing need for more quantitative and sensitive cancer diagnostic tests, particularly in prostate cancer.
What does Cellanyx do?
Cellanyx is developing the next generation cancer diagnostic. Cellanyx leverages advances in matrix biology, nanomedicine, and classical techniques in engineering, computer science and mathematics to provide a sensitive, objective and predictive solution to cancer diagnosis.
Ultimately, Cellanyx Diagnostics will provide a lab service that offers critical prognostic information before the radical prostatectomy decision point. Cellanyx leverages advances in matrix biology and nanofabrication to return discrete prognostic metrics based on biopsy analysis. Cellanyx's product will allow physicians and patients to make more personalized and cost-effective treatment decisions.
Patients who are diagnosed with prostate, colon, and breast cancer, are being monitored and/or are surgical candidates will benefit from Cellanyx's technology. Cellanyx's test ordered (at diagnosis) can provide physicians with objective, prognostic information to assist in their treatment decision process.
Cellanyx returns two metrics to the practicing physician: the first metric predicts the growth or oncogenic potential of a biopsy, and the second metric predicts the metastatic potential of the biopsy. With this information the practicing physician can better assess what treatment plan to pursue.
Cellanyx is also positioned to leverage its technology as a cell-based assay to identify compounds that reduce the growth and metstatic potential of cancer cells, thereby identifying compounds that are less toxic to the body and still effective in slowing down the growth and metastasis of aberrant cancer cells, reverting them, in principal, to a normal state.
How can our readers be of help?
Cellanyx is actively engaged in clinical studies to provide additional evidence of its technology's relevance and applicability to prostate cancer. Cellanyx has recruited a team of scientists and physicians from top universities around Boston and the United States. Cellanyx's team is directed and advised by seasoned diagnostic executives and practicing clinicians and academic scientists.
Cellanyx is interested in adding to its team and advisory board towards the commercialization and application of its technology to better serve patients at risk of prostate and other solid tumor cancers.
Specifically, Cellanyx is interested in meeting advisers, partners, and executives towards commercializing its prostate cancer prognostic, compound discovery / validation platform, and companion diagnostic.
The author is solely responsible for the content.
Meet Boston's coolest, smartest and most dynamic founders in our REEL Innovators video series!